Strengthening Africa Health Partnership

By Crystal Lubbe

February 20, 2025

The Africa health partnership between the Africa Centres for Disease Control and Prevention (Africa CDC) and the Global Health European & Developing Countries Clinical Trials Partnership 3 (Global Health EDCTP3) has resulted in a signed Memorandum of Understanding (MoU). Specifically, this agreement aims to enhance collaboration in health research, clinical trials, and pandemic preparedness across Africa.

Furthermore, the MoU includes a Joint Action Plan for 2025-2027, which focuses on six key areas of cooperation, such as strengthening the public health workforce, clinical trial ecosystems, and local manufacturing of health products. This partnership is crucial in addressing growing global health challenges, including climate change, conflicts, and limited public health funding.

Key Insights

  • Strengthening Health Workforce and Research Capacity: The MoU highlights the need for training and capacity building. This effort aims to enhance health research capabilities in sub-Saharan Africa.

  • Clinical Trials and Pandemic Preparedness: The agreement seeks to improve clinical trial ecosystems in African Union member states. It also advances research on new interventions for infectious diseases.

  • Local Manufacturing and Regulatory Frameworks: The partnership supports local production of vaccines, diagnostics, and treatments. Additionally, it strengthens regulatory pathways to ensure quality and safety.

  • Equitable Partnerships and Resource Mobilization: The MoU fosters action-driven, equitable partnerships. It also promotes resource mobilization by aligning priorities and leveraging public-private sector synergies.

Previous Collaborations and Challenges

The new MoU builds on a previous partnership established in 2021 between the EDCTP Association and Africa CDC, indicating a long-term commitment to collaborative health initiatives. This Africa health partnership addresses critical global health challenges, such as climate change, ongoing conflicts, and constrained financial resources for public health, which are significant concerns for public health agencies around the world. The initiative aligns with broader regional efforts, such as the Africa CDC Flagship Initiative on Health Data Governance, which aims to strengthen health data governance approaches across Africa.

Implications

The partnership is likely to yield positive implications for health economics in Africa by enhancing local manufacturing capabilities. This reduces reliance on external sources for vaccines and treatments, potentially lowering costs and leading to more sustainable public health solutions. By strengthening the health research workforce, clinical trial ecosystems, and pandemic preparedness, the partnership is expected to improve health outcomes across the continent. This includes better response mechanisms to infectious diseases and emerging health threats. Emphasising African-led solutions and local manufacturing is crucial for sustainable health innovations. This approach can lead to tailored and effective health interventions that are better suited to the specific needs of African populations.

The partnership between Africa CDC and Global Health EDCTP3 represents a significant step towards enhancing Africa’s health research, clinical trial capabilities, and pandemic preparedness. Ultimately, it aims to contribute to improved public health outcomes and sustainable health innovations in the region.

Reference url

Recent Posts

FDA Guidance on Overall Survival Assessment in Oncology Trials

By Staff Writer

August 20, 2025

Overall survival assessment serves as the gold standard for determining the true impact of oncology treatments, directly answering patient and provider questions such as: “How will this therapy affect my length of life?” According to the latest FDA guidance, robust overall survival assessment is ...
Guiding the Future of Digital Cardiac Rehabilitation: NICE’s Conditional Recommendations
The National Institute for Health and Care Excellence (NICE) has issued consultative draft guidance recommending six digital cardiac rehabilitation technologies for adults with cardiovascular disease (CVD). These technologies are conditionally recommended for use in the NHS during a three-year ev...
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit

By João L. Carapinha

August 19, 2025

A recent G-BA decision provides a systematic evaluation of Glofitamab Gemcitabine DLBCL, combined with Gemcitabine and Oxaliplatin (GemOx), for treating adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplantation. The review...